Comparative analysis of four sequencing platforms for methylation sequencing

Area of Science:

• Genomics and Epigenetics
• Molecular Biology
• Bioinformatics

Background:

• Methylation analysis is crucial for understanding gene regulation and disease.
• Plasma cell-free DNA (cfDNA) offers a non-invasive source for epigenetic studies.
• Evaluating sequencing platform performance is essential for reliable methylation data.

Purpose of the Study:

• To comprehensively assess and compare the performance of four leading sequencing platforms (GenoLab M, NovaSeq X, T7, and Salus Pro).
• To evaluate key metrics including sequencing quality, CpG coverage, data efficiency, and methylation level consistency using plasma cfDNA.
• To provide insights into platform consistency for researchers integrating multiple methylation datasets.

Main Methods:

• Analysis of plasma cfDNA samples across four distinct sequencing platforms.
• Assessment of critical performance metrics: sequencing quality, CpG site coverage, data processing efficiency, and methylation value reproducibility.
• Comparative analysis of results to identify platform-specific strengths and weaknesses.

Main Results:

• Detailed performance metrics for GenoLab M, NovaSeq X, T7, and Salus Pro platforms.
• Identification of variations in CpG coverage and methylation consistency across platforms.
• Evaluation of data efficiency and overall sequencing quality for each platform.

Conclusions:

• The study provides a comparative overview of four sequencing platforms for methylation analysis.
• Findings highlight the importance of platform selection based on specific research needs and desired data quality.
• Recommendations are offered to aid researchers in choosing the most suitable sequencing technology for cfDNA methylation studies.